The Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) Consortium. Focusing on clinically relevant and applicable AI tools voor HPB disease.
๐ Pancreas 2023 Wrapped! ๐พ
๐ October 2023: The use of radiomics ๐ค in pancreas surgery... future or present?!
๐ง Is radiomics already impacting your clinical practice? ๐ซต
This is the first tool to predict the risk of POPF ๐ณ
The first ever Radiomics ๐พ preoperative fistula risk score !!!
Development ๐ณ๐ฑ and external validation ๐ฎ๐น
๐ณ The radiomics-based preop FRS performed similarly to the existing scores ( ROC 0.8)
๐ช Great added value considering only CT derived data!
https://t.co/E6Brd9WDhv
Now in @BjsOpen!
Externally valid #radiomics pre-op fistula risk score (RAD-FRS) for Whipple! ๐ฎ๐น๐ณ๐ฑ
FIRST externally valid model โ Similar AUC (0.81) to (ua)FRS (0.79) in preop setting ๐ท
๐ @EwoutIngwersen, @JackieBereska and @PHAIRconsortium!
https://t.co/7jBtcfpGLR
Last week radiogist Hรฅvard Bjรธrke Jenssen from ๐ณ๐ด@Oslounivsykehus visited the ๐ณ๐ฑ @AmsterdamUMC HPB team!
Sharing and aligning HPB CT segmentation โ๏ธ strategies with Yung Nio, @JackieBereska@i_verpalen and others! ๐ธ
Visit finalized with the annual @AmsterdamUMC HPB BBQ!
Last week radiogist Hรฅvard Bjรธrke Jenssen from ๐ณ๐ด@Oslounivsykehus visited the ๐ณ๐ฑ @AmsterdamUMC HPB team!
Sharing and aligning HPB CT segmentation โ๏ธ strategies with Yung Nio, @JackieBereska@i_verpalen and others! ๐ธ
Visit finalized with the annual @AmsterdamUMC HPB BBQ!
The future of IPMN management ๐ will be based on two pillars
๐๏ธ Biomarkers and AI
๐ค Twelve AI based models to assess the risk of malignancy already exist!
๐ข Methodological quality and reliability still to be improvedโฆ letโs work on it!!
๐ read ๐https://t.co/U84qBoSA7R
@EurPancClub#EPC2023@BorisJanssen on behalf of @PHAIRconsortium!
AI residual cancer burden (RCB) to evaluate impact of NAT in resected pancreatic cancer!
RCB ๐ฌ
NAT vs. upfront: 2.2 vs. 10.3 mm2
p<0.0001
Survival ๐
Above vs. below median RCB: 24 vs. 30 months.
p=0.018
@EurPancClub#EPC2023@BorisJanssen on behalf of @PHAIRconsortium!
AI residual cancer burden (RCB) to evaluate impact of NAT in resected pancreatic cancer!
RCB ๐ฌ
NAT vs. upfront: 2.2 vs. 10.3 mm2
p<0.0001
Survival ๐
Above vs. below median RCB: 24 vs. 30 months.
p=0.018
#EAHPBA2023@EAHPBA
Segmentation model for ๐ฌ residual pancreatic cancer following neoadjuvant therapy (ISGPP-2)!
Model based on 528 pt, 14 centers, 7 countries๐ณ๐ฑ๐บ๐ธ๐ฉ๐ช๐ณ๐ด๐น๐ท๐ฐ๐ท๐ฆ๐บ, 4 scanner types!
Validated with by-scanner internal-external cross-validation ๐! F1 score of 0.78!
#EAHPBA2023@EAHPBA
Segmentation model for ๐ฌ residual pancreatic cancer following neoadjuvant therapy (ISGPP-2)!
Model based on 528 pt, 14 centers, 7 countries๐ณ๐ฑ๐บ๐ธ๐ฉ๐ช๐ณ๐ด๐น๐ท๐ฐ๐ท๐ฆ๐บ, 4 scanner types!
Validated with by-scanner internal-external cross-validation ๐! F1 score of 0.78!